PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Drug or technology

Adrenergic Beta-antagonists

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

JUN 8, 2026 · JOURNAL ARTICLE

A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from a Dutch societal perspective.

Journal of Medical Economics

Model-based cost-effectiveness analysis demonstrates mavacamten meets accepted Dutch societal willingness-to-pay thresholds using established Markov modeling methods and published trial data.

Important Confirmatory EvidenceDrug Therapy, Combination Carla L Zema Adrenergic Beta-antagonists

Reported

Incremental QALYs3.09

Incremental LYs3.17

Incremental discounted costs€49,388

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support